CureSearch for Children's Cancer funds and supportstargeted and innovative children's cancer research with measurableresults, and is the authoritative source of information and resourcesfor all those affected by children's cancer.
Despite overall improvements in survival rates, some types of cancer remain very difficult to treat and account for more than their share of child cancer deaths. Leukemia and central nervous system tumors remain prevalent and account for over half of diagnosed cancers among children. Other cancers have benefitted from decades of research, yet show very slow progress in outcomes for children. Survival rates for some cancers are as low as 30% within two years of diagnosis. And a handful of cancers showing modest progress still maintain cure rates of only 50%. So while the overall odds have improved, the degree to which research has defied the odds varies greatly depending on the type of cancer diagnosed.
CureSearch is committed to partner with academia and industry through a collaborative and interdisciplinary approach to address some of the most difficult problems facing the pediatric cancer research community today. To this end, CureSearch has initiated a new research pathway—one that challenges the field to accelerate the search in order to find the cure. Rather than relying on traditional, sometimes slow moving granting processes, we intend to support innovative, evidence-based strategies that address the field's most difficult to treat pediatric cancers. We will use social media and new technologies to build avenues for communication that can eliminate silos between commercial, medical, patient, and scientific audiences. And most importantly, we will show measurable results.
After an overhaul of our internal efficiencies, we are ready to dedicate donor dollars to targeted outcomes for patients and families. While a typical research investment is deemed successful when an article is published or simple outputs are achieved, we measure our success by achieving outcomes in the laboratory and for patients. This is a new day of measurable results in scientific research, and with our first annual "Acceleration Initiative," CureSearch plans to lead the way.
"Acceleration Initiative" grants are intended to fund innovative research that breaks down barriers in the field, and transforms the impact cancer researchers can make, by translating discoveries into clinical application within an accelerated timeframe.
A CureSearch "grand challenge" is a call for a specific scientific or technological innovation that will remove a critical barrier or identify a breakthrough toward improving childhood cancer outcomes--all with a high likelihood of impact and feasibility.
This year, CureSearch invites the greater scientific community to propose innovative research approaches addressing the following challenges:
Critical Barrier: Most cancer deaths are not caused by the primary disease; rather, it is the invasion and spreading of mutated cells to distant sites in the body (metastasized tumors) that tend to give a poor prognosis for the patient. To this end, there is very little known about metastatic disease in either pediatric or adult cancers. One of the biggest challenges to improving survival is to understand the biology and mechanism of metastatic disease and how to target it. This insight not only provides immediate potential for improving targeted therapies for children with these lethal cancers, but will enable the future development of new drugs for patients who otherwise have limited options for treatment.
Critical Barrier: Multidrug resistance, the principal mechanism by which many cancers develop resistance to chemotherapy drugs, is a major factor in the failure of many forms of chemotherapy. It affects patients with a variety of blood cancers and solid tumors.
Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. Therefore, experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic approaches are needed to rapidly identify and exploit novel resistance mechanisms.
Critical Barrier: The path from research discovery to the creation of new treatment approaches is extremely long. New concepts about the etiology and progression of cancer lead investigators to propose numerous questions to further understand and refine these concepts. But for these ideas to translate into clinical application for patients, work must move along a critical pipeline from discovery, to target validation, to pre-clinical drug development and ultimately to clinical trials. Keeping new ideas flowing along this therapeutic pipeline is paramount to ensuring development of new treatments for infants, children, adolescents and young adults with cancer. This challenge presents an opportunity to help accelerate drug development and delivery by funding innovative strategies that identify and address roadblocks along the therapeutic development pipeline, thereby increasing the movement of new treatments to the bedside.
For details and to apply, please visit proposalCENTRAL.
All programmatic inquires (including questions related to eligibility, application requirements, etc)
Al RoyEmail Al
All technical inquiries related to the online application system, proposalCENTRAL